Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 13/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21549697 | 0.93 | HDAC1 (0.36) | HDAC1HDAC2ALDH1A1LMNAEHMT2 | |
| SCHEMBL21549646 | 0.90 | HDAC1 (0.35) | HDAC1HDAC2ALDH1A1LMNAHDAC4 | |
| SCHEMBL18726574 | 0.84 | HDAC1 (0.37) | HDAC1HDAC2ALDH1A1LMNAEHMT2 | |
| SCHEMBL4348222 | 0.84 | HDAC1 (0.39) | HDAC1HDAC2ALDH1A1LMNAEHMT2 | |
| SCHEMBL29353376 | 0.84 | HDAC1 (0.37) | HDAC1HDAC2ALDH1A1LMNAEHMT2 | |
| SCHEMBL574827 | 0.84 | HDAC1 (0.37) | HDAC1HDAC2ALDH1A1LMNAEHMT2 | |
| SCHEMBL31005440 | 0.84 | HDAC1 (0.39) | HDAC1HDAC2ALDH1A1LMNAEHMT2 | |
| SCHEMBL9904994 | 0.83 | HDAC1 (0.36) | HDAC1HDAC2ALDH1A1LMNAEHMT2 | |
| SCHEMBL27076397 | 0.81 | HDAC1 (0.37) | HDAC1HDAC2ALDH1A1LMNAEHMT2 | |
| SCHEMBL42368 | 0.81 | ALDH1A1 (0.44) | HDAC1HDAC2ALDH1A1LMNAEHMT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165537-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| WO-2012078868-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | IMMUNOGEN, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165537-A1 | METHODS FOR THE PREPARATION OF CHARGED CROSSLINKERS | SCLY, STOM, STS | HDAC1 1195/4885HDAC2 1161/4885ALDH1A1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.